Hepatitis Research Review, Issue 38

In this issue:

Amiodarone + sofosbuvir: insights into cardiac DDI
Modelling HCV disease burden in the era of oral DAAs
Quantitative maternal HBsAg predicts infection in infants
DAAs effective in HCV-associated mixed cryoglobulinaemia
Sofosbuvir, velpatasvir, & GS-9857 effective in GT1 HCV
. . . and also in GT2, 3, 4, or 6 HCV infections
Inducing sustainable resistance to sofosbuvir
Exploring ‘immune tolerance’ in HBV infection
Level of fibrosis linked to HCC risk in chronic HBV
A therapeutic strategy for HBV-infected hepatocytes?

Please login below to download this issue (PDF)

Subscribe